Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. Placebo-controlled …

Introduction There is an unmet need for new treatments for idiopathic pulmonary fibrosis
(IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline …

Background Nintedanib is a tyrosine kinase inhibitor used in the treatment of progressive
fibrosing interstitial lung diseases (ILDs). We assessed the safety and tolerability of …

Objective Our aim was to investigate the effectiveness and tolerability of antifibrotics in a real-
world cohort of patients with rheumatoid arthritis-associated interstitial lung diseases (RA …

The identification of novel prognostic biomarkers might enhance individualized
management strategies in patients with idiopathic pulmonary fibrosis (IPF). Although several …

Purpose Pirfenidone and nintedanib unequivocally inhibit FVC decline, but have been
inconsistently linked to reduced mortality in phase III studies. On the contrary, real-world …

Antifibrotic therapy has changed the treatment paradigm for idiopathic pulmonary fibrosis
(IPF); however, a subset of patients still experienced rapid disease progression despite …

Objective No studies have demonstrated the real-world efficacy of antifibrotics for
progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated the efficacy …

1. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic
pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 2020; …